Site Search
Displaying results 41 - 50 of 573
Resource | Publications,
These guidelines provide new and updated recommendations and good practice statements in the following areas: starting ART, including initiating treatment outside the clinic and support for same-day ART start; frequency of clinical visits and ART refills; measuring adherence; tracing and re-engagement in care for all populations; psychosocial support for adolescents living with HIV; task sharing for diagnostic services; and service integration.
This guideline seeks to provide support to Member States, programme managers, health workers and other stakeholders seeking to achieve national and international goals to end the HIV epidemic as a public health threat by 2030.
Resource | Publications,
Persons with disabilities are disproportionately impacted by COVID-19, both directly because of infection, and indirectly because of restrictions to reduce the spread of the virus. Persons with disabilities are a diverse group, and the risks, barriers and impacts faced by them will vary in different contexts according to, among other factors, their age, gender identity, type of disability, ethnicity, sexual orientation, and migration status.
This document presents considerations and actions for the following stakeholders to ensure equity in access to vaccination against COVID‑19 for persons with disabilities.
Resource | Publications,
The WHO 2021 guideline promotes the use of optimal antiretroviral treatment (ART) regimens in all populations. Though new, more effective and better tolerated options with a higher genetic barrier to resistance are now available for adults, optimized treatment options for children lag significantly behind.
This sixth edition of the Optimal Formulary and Limited-use List supports the transition to optimal WHO-recommended ART regimens for infants and children, while giving due consideration to the rapidly evolving treatment landscape and the risks inherent in the uncertain timelines for pediatric drug development.
Resource | Publications,
This technical brief provides guidance for the provision of equitable, evidence-informed and human-rights-based services for prevention of mother-to-child transmission (PMTCT) of HIV, hepatitis B and C and syphilis among women who use drugs, and to support countries in their efforts towards elimination of mother-to-child transmission (EMTCT).
As a general principle, all pregnant and breastfeeding women who use drugs should have at least the same access to evidence-based services for PMTCT as women in other populations. Women should not be excluded from health care because of their substance use. All interventions should be voluntary, with informed consent and maintenance of confidentiality, including about a person’s drug use or HIV status.
Resource | Publications,
This document highlights 10 well established Risk Communication and Community Engagement (RCCE) principles that have proven their power. Together they put communities at the heart of the roll out of new vaccines, treatments and tests and promote trust, the critical ingredient for all community action. Informed, engaged and empowered communities are the bedrock for the arrival of new vaccines, treatments and tests that will be introduced to reduce the spread of COVID-19 and save lives. With communities fully engaged and actively participating through the full cycle of planning, delivery and assessment for biomedical tools, demand for these tools can be increased, leading to widespread and effective uptake and use.
Resource | Publications,
Globally, at the end of 2017, only 5 million – or 7% – of the 71 (62–79) million people chronically infected with HCV had cumulatively received treatment with DAAs. As countries continue to tackle the disease burden and service disruptions caused by the COVID-19 pandemic, it is critical to ensure that the recent momentum and gains in the response to hepatitis C are not lost. Against this backdrop, this report is a strong reminder to continue to invest in building resilient and sustainable health systems that are focused on universal health coverage.
Resource | Publications,
The current HIV program is reaching KPs and PLHIV for prevention and treatment of HIV. The integrated intervention to KPs and providing HCV related activities like prevention, early diagnosis and providing treatment to cure HCV infection would be the cost-effective approach to decrease the burden of HCV among them. The availability of effective treatment – Direct - Acting Antiviral (DAA) has prevented HCV related consequences and cured from HCV infections. The pangenotypic DAA do not require genotyping of the virus and current WHO guidelines recommends that all HCV infected people are treated with minimal lab investigations and follow up. This recommendation helps us to combat Hep C related complications and prevent morbidities and mortalities and provide opportunity to treat clients at all kind of health facilities.
Resource | Publications,
NCASC has summarized in PowerPoint how COVID-19 pandemic affected the delivery of key services of National HIV programme, and our ongoing efforts to ensure incessant delivery of HIV prevention, testing, treatment and care services.
Resource | Publications,
Antimalarial drug resistance has emerged as a threat to global malaria control efforts, particularly in the Greater Mekong subregion. Drawing on data collected through more than 1000 therapeutic efficacy studies as well as molecular marker studies of Plasmodium falciparum drug resistance, the Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019) presents a decade’s worth of data on drug efficacy and surveillance, as well as recommendations to monitor and protect the efficacy of malaria treatment in the decades to come.
Resource | Publications,
Women living with HIV have a six-fold increased risk of cervical cancer when compared to women without HIV. This higher risk is manifested throughout the lifecycle starting with an increased risk of acquiring human papilloma virus infection (HPV), more rapid progression to cancer, lower chances of regression of pre-cancer lesions, higher rates of recurrence following treatment.